AngioDynamics (NASDAQ:ANGO – Get Free Report) and Nano-X Imaging (NASDAQ:NNOX – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.
Volatility and Risk
AngioDynamics has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500. Comparatively, Nano-X Imaging has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500.
Earnings & Valuation
This table compares AngioDynamics and Nano-X Imaging”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AngioDynamics | $320.17 million | 1.59 | -$36.74 million | ($0.78) | -15.49 |
| Nano-X Imaging | $13.02 million | 2.09 | -$75.02 million | ($2.14) | -0.16 |
AngioDynamics has higher revenue and earnings than Nano-X Imaging. AngioDynamics is trading at a lower price-to-earnings ratio than Nano-X Imaging, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
89.4% of AngioDynamics shares are owned by institutional investors. Comparatively, 21.5% of Nano-X Imaging shares are owned by institutional investors. 6.0% of AngioDynamics shares are owned by insiders. Comparatively, 7.7% of Nano-X Imaging shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares AngioDynamics and Nano-X Imaging’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AngioDynamics | -10.12% | -4.49% | -2.96% |
| Nano-X Imaging | -926.05% | -116.93% | -100.67% |
Analyst Ratings
This is a breakdown of current ratings for AngioDynamics and Nano-X Imaging, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AngioDynamics | 1 | 1 | 2 | 1 | 2.60 |
| Nano-X Imaging | 1 | 2 | 2 | 1 | 2.50 |
AngioDynamics currently has a consensus price target of $19.00, indicating a potential upside of 57.28%. Nano-X Imaging has a consensus price target of $4.33, indicating a potential upside of 1,152.41%. Given Nano-X Imaging’s higher probable upside, analysts clearly believe Nano-X Imaging is more favorable than AngioDynamics.
Summary
AngioDynamics beats Nano-X Imaging on 8 of the 13 factors compared between the two stocks.
About AngioDynamics
AngioDynamics, Inc. develops, manufactures and markets medical devices used in minimally invasive procedures. Its products are designed for clinicians in areas including vascular access, peripheral vascular disease and oncology. The company’s offerings include vascular access devices such as ports and catheters, as well as technologies used in vascular intervention and cancer treatment. These include the Auryon atherectomy system, which is used to treat certain peripheral arterial conditions, and the NanoKnife System, which uses irreversible electroporation in tumor ablation procedures.
About Nano-X Imaging
Nano-X Imaging Ltd. is an Israel-based medical technology company focused on expanding access to diagnostic imaging. The company develops digital X-ray systems and related technologies designed to provide medical imaging in locations that may have limited access to conventional radiology equipment. Its primary product is the Nanox.ARC, a digital tomosynthesis system intended to generate two- and three-dimensional medical images using a proprietary cold-cathode X-ray source. Nano-X also offers the Nanox.CLOUD platform, which is designed to connect imaging devices with radiologists and other healthcare professionals for image interpretation, workflow management, and related services.
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.
